PolyPeptide Group AG
PPGN.SW - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.39B
Close$
$-18.70
145.2% downside
Current Fair Value
145.2% downsideOvervalued by 145.2% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.39 Billion |
|---|---|
| Enterprise Value | $1.55 Billion |
| Earnings per Share | $-0.64 |
| Beta | 0.97 |
| Outstanding Shares | 33,016,410 |
Return
| Return on Equity | -5.75% |
|---|---|
| Return on Assets | -2.35% |
| Return on Invested Capital | 3.83% |
Valuation & Multiples
| P/E Ratio | 105.67 |
|---|---|
| PEG | -78.76 |
| Price to Sales | 1.65 |
| Price to Book Ratio | 4.14 |
| Enterprise Value to Revenue | 1.87 |
| Enterprise Value to EBIT | 62.27 |
| Enterprise Value to Net Income | -77 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | 0.62 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$0.06
Consensus analyst estimateRevenue Estimate
$201.25 M
Consensus analyst estimateNext Earnings Call
Expected Date
March 9, 2027
EPS Estimate
$0.36
Consensus analyst estimateRevenue Estimate
$234.41 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About PolyPeptide Group AG
1,469 employees
CEO: Juan Jose Gonzalez
Operating globally, PolyPeptide Group AG functions as a prominent contract development and manufacturing organization (CDMO). The company specializes in producing both proprietary and generic GMP-certified peptides, which are supplied to...